Screening for coronary calcium may provide an impetus for physicians to initiate preventive cardiovascular therapies in patients who have coronary calcium, but persistence with the medications is no better than in patients who are started on therapies without a coronary calcium test, said Allen J. Taylor, MD
Screening for coronary calcium may provide an impetus for physicians to initiate preventive cardiovascular therapies in patients who have coronary calcium, but persistence with the medications is no better than in patients who are started on therapies without a coronary calcium test, said Allen J. Taylor, MD.
At present, the American Heart Association (AHA) and American College of Cardiology (ACC) consider screening for coronary artery calcium to be a reasonable test in patients with an intermediate risk of a cardiovascular event based on risk factor profiling.
As part of a population screening study, 1,640 men without known coronary heart disease (CHD) were screened for CHD risk factors and for coronary artery calcium using electron beam computed tomography. The patients were followed for up to 6 years via telephone interviews, during which subsequent "ever use" and "consistent use" of statins and aspirin were recorded.
Almost one-fourth (22.4%) of patients had coronary artery calcium detected at baseline. At study entry, these patients were twice as likely to be using either a statin or aspirin than those without coronary calcium on their baseline test (9.9% vs. 4.7%, respectively).
During follow-up, the use of statins and aspirin increased progressively in both groups, but by 6 years statin use was 3 times more likely in patients with versus those without coronary calcium (48.5% vs. 15.5%; P <.001), and aspirin use was almost twice as likely (53.0% vs. 32.3%; P <.01).
Statin use was related to the presence of coronary artery calcium. Compared with the patients without coronary artery calcium, the ever use of a statin was 2 times greater in the patients with coronary artery calcium who were not at their low-density lipoprotein (LDL) cholesterol National Cholesterol Education Program (NCEP) goal at baseline and more than 4 times greater among those with an LDL cholesterol level below their NCEP goal.
"Within the patient-physician interaction, there was a recognition of risk from a calcium score and that led to this 3-fold increase in either statin use or aspirin use over those without calcium independent of other risk factors, and led to more appropriate use of the medicines," said Dr. Taylor, chief of cardiology at Walter Reed Army Medical Center in Washington, D.C.
After controlling for NCEP recommendations on initiating statin therapy and behavioral, demographic, and psychological variables, persistence with a statin or aspirin was not related to coronary artery calcium. Even so, only 10% to 20% of patients with or without coronary calcium failed to stay on their statin or aspirin, said Dr. Taylor.
"This was a very persistent group," he said. "If anything, the clinicians may have been driving the persistence because if the patients didn't have calcium, they still had risk factors that required treatment with a statin. If they had calcium, it resulted in greater use."
These are the first data to demonstrate that coronary artery calcium screening can influence management decisions, he said. Based on the findings, he added, refinement of risk with a calcium score in intermediate-risk patients is appropriate.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.